Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tonix Pharma ( (TNXP) ) has provided an announcement.
On September 29, 2025, Tonix Pharmaceuticals announced plans to advance its TNX-2900 program for Prader-Willi syndrome into a Phase 2 clinical trial. The trial will assess the safety, tolerability, and efficacy of TNX-2900 in children aged 8 to 17.5 years, with the study expected to start in 2026. This development marks a significant step in Tonix’s efforts to address rare diseases, potentially enhancing its market position and offering new treatment options for stakeholders.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by strong corporate events, particularly the FDA approval of Tonmya, which significantly boosts its market potential. However, challenges in profitability and valuation weigh down the score. Mixed technical indicators suggest cautious optimism.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders and rare diseases. The company is advancing its pipeline with product candidates like TNX-2900, targeting conditions such as Prader-Willi syndrome.
Average Trading Volume: 1,503,513
Technical Sentiment Signal: Strong Sell
Current Market Cap: $212.2M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.